The company's live attenuated vaccine strain of the bacterium Shigella induces broad protection against different species and serotypes of this pathogen, preventing diarrheal diseases in travelers and people living in endemic regions of low- and middle-income countries. EveliQure is an innovative game-changer in vaccine development, passionate about improving the quality of life for all by providing medical solutions that fight diarrheal diseases.